Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CMV chemotherapy for advanced transitional cell carcinoma.

G M Jeffery1, G M Mead

  • 1CRC Wessex Regional Medical Oncology Unit, Southampton General Hospital, UK.

British Journal of Cancer
|September 1, 1992
PubMed
Summary

Combination chemotherapy (CMV) showed limited efficacy in metastatic transitional cell carcinoma (TCC). Cisplatin, methotrexate, and vinblastine resulted in a 24% complete remission rate and a median survival of 7 months for TCC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Sex cord stromal testicular tumors: a clinical series--uniformly stage I disease.

The Journal of urology·2009
Same author

Bladder carcinoma recurrence post-cystectomy simulating rectal carcinoma.

Clinical radiology·2007
Same author

Case series: adult testicular dermoid tumours--mature teratoma or pre-pubertal teratoma?

International urology and nephrology·2006
Same author

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.

Annals of oncology : official journal of the European Society for Medical Oncology·2006

Area of Science:

  • Oncology
  • Urologic Oncology
  • Medical Oncology

Background:

  • Metastatic transitional cell carcinoma (TCC) of the urinary tract presents a significant treatment challenge.
  • Limited effective therapeutic options exist for advanced TCC, necessitating research into novel chemotherapy regimens.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of a combination chemotherapy regimen (CMV) in patients with metastatic TCC.
  • To determine the response rates and survival outcomes associated with CMV treatment for advanced TCC.

Main Methods:

  • A cohort of 43 patients with metastatic TCC received combination chemotherapy (CMV) comprising cisplatin, methotrexate, and vinblastine.
  • Treatment involved intravenous administration on specific days, with cycles recycled every 22 days for a maximum of six cycles.

Related Experiment Videos

  • Response was assessed in 33 patients with measurable disease.

    • Main Results:

    • A complete remission (CR) rate of 24% (8 out of 33 patients with measurable disease) was observed.
    • The median survival for patients achieving CR was 13 months, while the overall median survival for all 43 patients was 7 months.
    • Only three patients remained alive at the time of reporting, with two being disease-free.

    Conclusions:

    • The CMV chemotherapy regimen demonstrated limited efficacy in achieving durable responses and long-term survival in metastatic TCC.
    • There is a critical need for the development of more effective and less toxic chemotherapy strategies for patients diagnosed with metastatic TCC.